Nuvectis Pharma (NVCT) Retained Earnings (2021 - 2026)

Nuvectis Pharma has disclosed Retained Earnings across 6 years of filings, most recently posting -$105.7 million for Q1 2026.

• Retained Earnings for Q1 2026 came in at -$105.7 million, down 34.48% year-over-year; the trailing twelve-month figure through Mar 2026 was -$105.7 million (down 34.48% YoY), and the FY2025 annual result was -$99.7 million, down 36.1% from the prior year.
• Retained Earnings came in at -$105.7 million for Q1 2026 at Nuvectis Pharma, down from -$99.7 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$15.8 million in Q1 2022 to a low of -$105.7 million in Q1 2026.
• The 5-year median for Retained Earnings is -$58.4 million (2024), against an average of -$58.5 million.
• Across the five-year window, Retained Earnings plunged 147.95% in 2022 and plunged 34.48% in 2026, its largest moves.
• Nuvectis Pharma's Retained Earnings stood at -$32.0 million in 2022, then sank by 69.6% to -$54.2 million in 2023, then plunged by 35.03% to -$73.2 million in 2024, then sank by 36.1% to -$99.7 million in 2025, then dropped by 6.03% to -$105.7 million in 2026.
• The last three Retained Earnings figures came in at -$105.7 million (Q1 2026), -$99.7 million (Q4 2025), and -$92.4 million (Q3 2025), per Business Quant data.